Province of South Holland awards a subsidy of €200,000 to a joint project between SeraNovo and PercurosTuesday, January 30, 2018
Over time this will create a new wave of medications in fields including Cancer, HIV and Arthritis. The test of Percuros will be safer and cheaper than commercially available tests, while granting SeraNovo one of the best testing platforms for simulating the human gastro-intestinal tract to optimise their technology and prove its efficacy. Combining these two innovations will allow SeraNovo to bring more cures to patients and come one step closer to solving a big problem the pharmaceutical industry has with declining solubility of newly developed medicines.
Pharming reports positive data from first investigator-initiated study of rhC1-Inhibitor (RUCONEST®) in Contrast-induced Nephropathy
In Ovo has been given an investment of several million euros
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatiod Arthritis to be presented at 2018 ACR/ARHP Annual Meeting